13F reference period
Q3 2026
Security Snapshot
Generate Biomedicines, Inc. - COMMON STOCK (GENB) Institutional Ownership
CUSIP: 370920100
13F Institutional Holders and Ownership History from Q1 2026 to Q3 2026
Institutions Reporting
51
Shares (Excl. Options)
15.53M
Full value: 15,533,445 · shares · 30 Sep 2026Price
$15.02
The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- GENB on Nasdaq
- All holders as of 30 Sep 2026
- Q3 2026
- Total 13F shares
- 15,533,445
- Total 13F value
- $233,385,590
- Portfolio coverage rank
- 0%
- Share change
- +3,110,201
- Value change
- +$44,594,784
- Number of holders
- 51
- Shares outstanding
- 128,325,054
- SEC-reported price per share
- $12.26
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- GENB - Generate Biomedicines, Inc. - COMMON STOCK is tracked under CUSIP 370920100.
- 51 institutions reported positions in Q3 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 86 to 51 between Q2 2026 and Q3 2026.
- SEC-reported value moved from to
$1.69B
Full value: $1,687,831,069 · USD · 30 Jun 2026.$233.39M
Full value: $233,385,590 · USD · 30 Sep 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 51 institutions filings for Q3 2026.
Security key
370920100
13F reference period
Q3 2026
13F holders
51
13D/G owners
3
CIK / CUSIP context first
Open Q3 2026 holders
GENB full holder history
Generate Biomedicines, Inc. SEC filings
Generate Biomedicines, Inc. company facts
Generate Biomedicines, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 370920100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
GENB
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Flagship Pioneering, LLC | 49% | $802,584,512 | 62,701,915 | Afeyan Noubar | 31 Mar 2026 | |||
| FMR LLC | 5.6% | $88,102,849 | 7,186,203 | FMR LLC | 30 Sep 2026 | |||
| Nally Michael | 5.2% | $88,563,853 | 6,919,051 | Nally Michael | 31 Mar 2026 |
As of 30 Sep 2026,
51
institutional investors reported holding
shares of
Generate Biomedicines, Inc. - COMMON STOCK (GENB).
This represents
12%
of the company’s total
outstanding shares.
15.53M
Full value: 15,533,445 · shares · 30 Sep 2026128.33M
Full value: 128,325,054 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
12%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Capital World Investors | 3.3% | 4,201,990 | -0.32% | 0.01% | $63,113,890 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.7% | 2,235,590 | +97% | 0% | $33,578,562 |
| ARK Investment Management LLC | 1.5% | 1,964,661 | +53% | 0.17% | $29,509,210 |
| BANQUE PICTET & CIE SA | 1.4% | 1,773,043 | 0.26% | $26,631,106 | |
| Davern Capital Partners, LP | 0.64% | 824,679 | 0% | 2.4% | $12,386,679 |
| Siren, L.L.C. | 0.57% | 736,104 | 0% | 0.26% | $11,056,282 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.57% | 729,083 | -0.81% | 0% | $10,953,558 |
| STATE STREET CORP | 0.43% | 546,337 | +3.8% | 0% | $8,205,982 |
| MORGAN STANLEY | 0.41% | 522,410 | +38% | 0% | $7,846,602 |
| VANGUARD FIDUCIARY TRUST CO | 0.16% | 204,175 | +16% | 0% | $3,066,709 |
| TD ASSET MANAGEMENT INC | 0.14% | 180,000 | +255% | 0% | $2,775,600 |
| ALPS ADVISORS INC | 0.13% | 170,042 | +31% | 0.01% | $2,554,031 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.13% | 169,760 | +1.5% | 0% | $2,549,795 |
| Prosight Management, LP | 0.11% | 144,756 | 0.42% | $2,174,235 | |
| Savant Capital, LLC | 0.11% | 139,418 | 0.01% | $2,094,060 | |
| Quadrature Capital Ltd | 0.09% | 120,301 | +282% | 0.01% | $1,806,921 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 0.09% | 115,993 | +37% | 0% | $1,742,215 |
| Affinity Asset Advisors, LLC | 0.08% | 100,000 | -75% | 0.09% | $1,502,000 |
| Amova Asset Management Americas, Inc. | 0.06% | 78,531 | +105% | 0.01% | $1,178,750 |
| Sumitomo Mitsui Trust Group, Inc. | 0.06% | 78,531 | +103% | 0% | $1,179,536 |
| Bank Pictet & Cie (Europe) AG | 0.06% | 77,778 | 0.02% | $1,168,226 | |
| BNP PARIBAS FINANCIAL MARKETS | 0.05% | 62,520 | 0% | $939,050 | |
| BOLTON SECURITIES CORPORATION | 0.04% | 45,000 | 0.03% | $675,900 | |
| CenterBook Partners LP | 0.03% | 43,373 | -67% | 0.03% | $651,462 |
| Dynamic Advisor Solutions LLC | 0.03% | 40,816 | 0.02% | $613,056 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
3
Headline period
Q3 2026
Rows shown
1-3 of 3